Nuzenio

Tradingview Prax

Tradingview Prax entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 10 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Praxis Precision Medicines Q2 Earnings Call Highlights - TradingViewTradingView · Fri, 07 Aug 2026 08:04:00 GMTPraxis Precision Medicines, Inc. Stock 12‑Month Price Target Raised to $620.95, Implies 95% Upside - TradingViewTradingView · Thu, 06 Aug 2026 23:20:28 GMTPRAX: Two late-stage NDAs near approval, launches and commercial buildout fully underway - TradingViewTradingView · Thu, 06 Aug 2026 15:06:51 GMTPraxis Precision Medicines Q2 2026: Net loss $(83.7M), EPS $(2.87) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 12:41:00 GMTPRAX: Net loss increased to $83.7M in Q2 2026 as R&D and G&A spending rose for late-stage CNS programs - TradingViewTradingView · Thu, 06 Aug 2026 12:35:10 GMTPRAX: Four CNS therapies with blockbuster potential target >$20B peak sales by 2028 - TradingViewTradingView · Thu, 06 Aug 2026 12:33:45 GMTPraxis Precision Q2 net loss widens on higher expenses - TradingViewTradingView · Thu, 06 Aug 2026 12:12:51 GMTPRAX: FDA progress and strong cash position support late-stage CNS pipeline and commercial readiness - TradingViewTradingView · Thu, 06 Aug 2026 12:05:14 GMT

Timeline

Fri, 07 Aug 2026 08:04:00 GMTPraxis Precision Medicines Q2 Earnings Call Highlights - TradingView
Thu, 06 Aug 2026 23:20:28 GMTPraxis Precision Medicines, Inc. Stock 12‑Month Price Target Raised to $620.95, Implies 95% Upside - TradingView
Thu, 06 Aug 2026 15:06:51 GMTPRAX: Two late-stage NDAs near approval, launches and commercial buildout fully underway - TradingView
Thu, 06 Aug 2026 12:41:00 GMTPraxis Precision Medicines Q2 2026: Net loss $(83.7M), EPS $(2.87) — 10-Q Summary - TradingView
Thu, 06 Aug 2026 12:35:10 GMTPRAX: Net loss increased to $83.7M in Q2 2026 as R&D and G&A spending rose for late-stage CNS programs - TradingView
Thu, 06 Aug 2026 12:33:45 GMTPRAX: Four CNS therapies with blockbuster potential target >$20B peak sales by 2028 - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tradingview Prax.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.